Doctor of Osteopathy Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Hannah Pile

Dermatology Bellevue, WA Doctor of Osteopathy

NPI 1255890257 CMS profile 11304407

1515 116Th Ave Ne Ste 307, Bellevue, WA 98004

Open in the dashboard

General payments

$6,484

290 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Hannah Pile of Bellevue, WA is reported in the CMS Open Payments database as having received $6,484 across 290 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 70th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,122 152
2024 General $2,557 110
2023 General $642 24
2022 General $150 3
2021 General $13 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hannah Pile
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Hannah Pile were reported at $3,122. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Hannah Pile Dermatology median Middle half National median
2019 $0 $454 $129–$1,240 $163
2020 $0 $235 $81–$756 $114
2021 $13 $377 $108–$1,108 $132
2022 $150 $514 $143–$1,391 $149
2023 $642 $607 $159–$1,674 $160
2024 $2,557 $751 $204–$1,903 $164
2025 $3,122 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,043 48 payments
  2. Genzyme Corporation $690 24 payments
  3. Incyte Corporation $644 33 payments
  4. Sun Pharmaceutical Industries Inc. $565 27 payments
  5. UCB, Inc. $516 19 payments
  6. Lilly USA, LLC $443 14 payments
  7. E.R. Squibb & Sons, L.L.C. $411 18 payments
  8. Regeneron Healthcare Solutions, Inc. $360 18 payments
  9. Janssen Biotech, Inc. $355 22 payments
  10. Dermavant Sciences, Inc. $292 17 payments
  11. Other $1,166 50 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,475 289 payments
  2. Education $10 1 payment
Products named General payments · program years 2021–2025
  1. DUPIXENT $793 30 payments
  2. OPZELURA $644 33 payments
  3. ILUMYA $520 22 payments
  4. Bimzelx $516 19 payments
  5. RINVOQ $433 24 payments
  6. SOTYKTU $411 18 payments
  7. TREMFYA $355 22 payments
  8. SKYRIZI Immunology $349 12 payments
  9. VTAMA $336 20 payments
  10. SKYRIZI Immunology $254 11 payments
  11. Other $2,395 113 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

290 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record